Search Results

There are 2687 results for: content related to: Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities–the BEGAMI study

  1. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff and Christian Lerch

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD006739.pub2

  2. Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 165–174, Dr Rajesh Krishna, Dr Arthur Bergman, Dr Patrick Larson, Mr Josee Cote, Dr Kenneth Lasseter, Ms Stacey Dilzer, Dr Amy Wang, Dr Wei Zeng, Mr Li Chen, Dr John Wagner and Dr Gary Herman

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296523

  3. Glucagon-like peptide analogues for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Deepson S. Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman Waugh and Ailsa Snaith

    Published Online : 5 OCT 2011, DOI: 10.1002/14651858.CD006423.pub2

  4. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

    International Journal of Clinical Practice

    Volume 64, Issue 5, April 2010, Pages: 562–576, T. Seck, M. Nauck, D. Sheng, S. Sunga, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda and for the Sitagliptin Study 024 Group

    Version of Record online : 4 MAR 2010, DOI: 10.1111/j.1742-1241.2010.02353.x

  5. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

    Clinical Pharmacology & Therapeutics

    Volume 78, Issue 6, December 2005, Pages: 675–688, Gary A. Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka, Amy Q. Wang, Wei Zeng, Donald Musson, Gregory Winchell, Michael J. Davies, Steven Ramael, Keith M. Gottesdiener and John A. Wagner

    Version of Record online : 7 DEC 2005, DOI: 10.1016/j.clpt.2005.09.002

  6. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1101–1110, M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman and B. J. Goldstein

    Version of Record online : 18 JUL 2013, DOI: 10.1111/dom.12145

  7. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes

    European Journal of Clinical Investigation

    Volume 46, Issue 1, January 2016, Pages: 70–79, Chin-Hsiao Tseng

    Version of Record online : 17 DEC 2015, DOI: 10.1111/eci.12570

  8. You have free access to this content
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 2, March 2007, Pages: 194–205, M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, P. P. Stein and Sitagliptin Study 024 Group

    Version of Record online : 26 JAN 2007, DOI: 10.1111/j.1463-1326.2006.00704.x

  9. You have free access to this content
    Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells

    British Journal of Pharmacology

    Volume 167, Issue 7, December 2012, Pages: 1506–1519, Chun-Yao Huang, Chun-Ming Shih, Nai-Wen Tsao, Yi-Wen Lin, Po-Hsun Huang, Shinn-Chih Wu, Ai-Wei Lee, Yung-Ta Kao, Nen-Chung Chang, Hironori Nakagami, Ryuichi Morishita, Keng-Liang Ou, Wen-Chi Hou, Cheng-Yen Lin, Kuo-Gi Shyu and Feng-Yen Lin

    Version of Record online : 6 NOV 2012, DOI: 10.1111/j.1476-5381.2012.02102.x

  10. Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects

    The Journal of Clinical Pharmacology

    Volume 46, Issue 8, August 2006, Pages: 876–886, Dr Gary A. Herman, Dr Arthur Bergman, Dr Fang Liu, Ms Cathy Stevens, Dr Amy Q. Wang, Mr Wei Zeng, Dr Li Chen, Ms Karen Snyder, Ms Deborah Hilliard, Mr Michael Tanen, Dr Wesley Tanaka, Dr Alan G. Meehan, Dr Kenneth Lasseter, Ms Stacy Dilzer, Dr Robert Blum and Dr John A. Wagner

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006289850

  11. You have free access to this content
    Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 66, Issue 1, July 2008, Pages: 36–42, Goutam C. Mistry, Arthur J. Bergman, Wei Zheng, David Hreniuk, Miguel A. Zinny, Keith M. Gottesdiener, John A. Wagner, Gary A. Herman and Marcella Ruddy

    Version of Record online : 22 MAY 2008, DOI: 10.1111/j.1365-2125.2008.03148.x

  12. Multiple Doses of Sitagliptin, a Selective DPP-4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

    The Journal of Clinical Pharmacology

    Volume 49, Issue 10, October 2009, Pages: 1157–1167, D. Hamish Wright, Gary A. Herman, Andrea Maes, Qi Liu, Amy O. Johnson-Levonas and John A. Wagner

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009341653

  13. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 6, June 2013, Pages: 531–537, L. Ohlsson, W. Alsalim, R. D. Carr, A. Tura, G. Pacini, A. Mari and B. Ahrén

    Version of Record online : 7 FEB 2013, DOI: 10.1111/dom.12062

  14. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

    Hepatology Research

    Yasushi Okura, Tadashi Namisaki, Kei Moriya, Mitsuteru Kitade, Kosuke Takeda, Kosuke Kaji, Ryuichi Noguchi, Norihisa Nishimura, Kenichiro Seki, Hideto Kawaratani, Hiroaki Takaya, Shinya Sato, Yasuhiko Sawada, Naotaka Shimozato, Masanori Furukawa, Keisuke Nakanishi, Soichiro Saikawa, Takuya Kubo, Kiyoshi Asada and Hitoshi Yoshiji

    Version of Record online : 13 FEB 2017, DOI: 10.1111/hepr.12860

  15. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 7, July 2008, Pages: 545–555, J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda and D. Williams-Herman

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1463-1326.2008.00914.x

  16. You have full text access to this OnlineOpen article
    Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care

    International Journal of Clinical Practice

    Volume 69, Issue 3, March 2015, Pages: 281–291, M. E. Nyeland, U. J. Ploug, A. Richards, L. Garcia Alvarez, D. Demuth, A. Muthutantri, R. Skovgaard and M. Evans

    Version of Record online : 10 OCT 2014, DOI: 10.1111/ijcp.12575

  17. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 8, August 2010, Pages: 648–658, A. J. Scheen

    Version of Record online : 27 FEB 2010, DOI: 10.1111/j.1463-1326.2010.01212.x

  18. A concise review of the bioanalytical methods for the quantitation of sitagliptin, an important dipeptidyl peptidase-4 (DPP4) inhibitor, utilized for the characterization of the drug

    Biomedical Chromatography

    Volume 30, Issue 5, May 2016, Pages: 749–771, P. S. Suresh, Nuggehally R. Srinivas and Ramesh Mullangi

    Version of Record online : 14 MAR 2016, DOI: 10.1002/bmc.3705

  19. You have free access to this content
    The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study

    Alimentary Pharmacology & Therapeutics

    Volume 36, Issue 4, August 2012, Pages: 379–390, J. E. Stevens, M. Horowitz, C. F. Deacon, M. Nauck, C. K. Rayner and K. L. Jones

    Version of Record online : 28 JUN 2012, DOI: 10.1111/j.1365-2036.2012.05198.x

  20. You have full text access to this OnlineOpen article
    Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts

    Journal of Cellular and Molecular Medicine

    Volume 19, Issue 2, February 2015, Pages: 418–429, Tsung-Ming Lee, Wei-Ting Chen, Chen-Chia Yang, Shinn-Zong Lin and Nen-Chung Chang

    Version of Record online : 11 NOV 2014, DOI: 10.1111/jcmm.12465